Patents by Inventor Jean-Marie-Viktor de Vry

Jean-Marie-Viktor de Vry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl and heteroaryl sulfonates
    Patent number: 6919470
    Abstract: The invention relates to novel aryl and heteroaryl sulfonates of formula (Ia) and to methods for producing them and to novel aryl and heteroaryl sulfonates of formula (I) for treating and/or preventing diseases, especially for treating pain and neurodegenerative diseases, A representing (C6-C10)-aryl or 5-10-membered heteroaryl, D representing (C6-C10)-arylene or 5-10-membered heteroarylene, R1 representing (C4-C8)-alkyl, (C2-C8)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: —O—, —S—, —SO— and —SO2—, (C2-C8)-alkenyl or (C2-C8)-alkinyl, in formula (Ia); and R1 representing (C3-C8)-alkyl, (C2-C8)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: —O—, —S—,—SO— and —SO2—, (C2-C8)-alkenyl or (C2-C8)-alkinyl.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 19, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor de Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Volker Hinz, Swen Allerheiligen
  • Phenoxyphenyl alkanesulphonates
    Publication number: 20040214886
    Abstract: The invention relates to novel phenoxyphenyl alkanesulphonates, processes for their preparation, their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment of states of pain and neurodegenerative disorders
    Type: Application
    Filed: May 20, 2004
    Publication date: October 28, 2004
    Applicant: Bayer Aktiengesellschaft
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor De Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Jan-Bernd Lenfers
  • Phenoxyphenyl alkanesulphonates
    Patent number: 6756409
    Abstract: The invention relates to novel phenoxyphenyl alkanesulphonates, processes for their preparation, their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment of states of pain and neurodegenerative disorders.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: June 29, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor De Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Jan-Bernd Lenfers
  • Substituted &agr;, &bgr;-anellated butyrolactones
    Patent number: 6723718
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: April 20, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Aryl and heteroaryl sulfonates
    Publication number: 20030232802
    Abstract: The invention relates to novel aryl and heteroaryl sulfonates of formula (Ia) and to methods for producing them and to novel aryl and heteroaryl sulfonates of formula (I) for treating and/or preventing diseases, especially for treating pain and neurodegenerative diseases, A representing (C6-C10)-aryl or 5-10-membered heteroaryl, D representing (C6-C10)-arylene or 5-10-membered heteroarylene, R1 representing (C4-C8)-alkyl, (C2-C8)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: —O—, —S—, —SO—and —SO2—, (C2-C8)-alkenyl or (C2-C8)-alkinyl, in formula (Ia); and R1 representing (C3-C8)-alkyl, (C2-C8)-alkyl, the carbon chain being interrupted by one or two heteroatoms or groups chosen from the following group: —O—, —S—,—SO—and —SO2—, (C2-C8)-alkenyl or (C2-C8)-alkinyl.
    Type: Application
    Filed: May 12, 2003
    Publication date: December 18, 2003
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor de Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Volker Hinz, Swen Allerheiligen
  • Substituted alpha, beta-anellated butyrolactones
    Publication number: 20030158424
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Application
    Filed: July 25, 2002
    Publication date: August 21, 2003
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Muller, Jorg Baumgarten, Karsten von dem Bruch, Gerhard Muller, Udo Stropp, Ervin Horvath, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6573278
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 3, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Aryl sulphonamide amino acid esters and analogues
    Patent number: 6545050
    Abstract: The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: April 8, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Viktor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6525087
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: February 25, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Phenoxyphenyl alkanesulphonates
    Publication number: 20030022934
    Abstract: The invention relates to novel phenoxyphenyl alkanesulphonates, processes for their preparation, their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment of states of pain and neurodegenerative disorders
    Type: Application
    Filed: September 26, 2001
    Publication date: January 30, 2003
    Inventors: Markus Heil, Heinrich Meier, Paul Naab, Arnd Voerste, Jean-Marie-Viktor De Vry, Dirk Denzer, Frank Mauler, Klemens Lustig, Jan-Bernd Lenfers
  • Substituted &agr;, &bgr;-anellated butyrolactones
    Patent number: 6462074
    Abstract: The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: October 8, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted &bgr;,&ggr;-anellated lactones
    Patent number: 6433004
    Abstract: The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: August 13, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Arylsulfonamides and analogues
    Publication number: 20020072529
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: June 11, 2001
    Publication date: June 13, 2002
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Substituted bicyclic lactones
    Patent number: 6376539
    Abstract: The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 23, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Use of known agonists of the central cannabinoid receptor CB1
    Publication number: 20010034344
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: May 29, 2001
    Publication date: October 25, 2001
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6284788
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: September 4, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6262112
    Abstract: The present invention relates to new aryl ether sulphonamides and analogs, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: July 17, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system
    Patent number: 6194428
    Abstract: The invention relates to the use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives, some of which are known, for the production of medicaments, in particular for the treatment of cerebral disorders.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: February 27, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus Urbahns, Hans-Georg Heine, Bodo Junge, Rudolf Schohe-Loop, Henning Sommermeyer, Thomas Glaser, Reilinde Wittka, Jean-Marie-Viktor de Vry
  • Use of 1,2-Bridged 1,4-dihydropyridines as medicaments
    Patent number: 6147087
    Abstract: The present invention relates to the new use of 1,2-bridged 1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 and a have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.
    Type: Grant
    Filed: July 28, 1999
    Date of Patent: November 14, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus Urbahns, Hans-Georg Heine, Bodo Junge, Thomas Glaser, Reilinde Wittka, Jean-Marie-Viktor De Vry, Henning Sommermeyer
  • 2,3-bridged 1,4-dihydropyridines, and their use as medicaments
    Patent number: 6121284
    Abstract: The present invention relates to new 2,3-bridged 1,4-dihydropyridines of the general formula (I), ##STR1## in which R, R.sup.1, R.sup.2, D and E have the meaning given in the description, processes for their preparation and their use as medicaments, preferably for treatment of the central nervous system.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: September 19, 2000
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus Urbahns, Siegfried Goldmann, Hans-Georg Heine, Bodo Junge, Rudolf Schohe-Loop, Henning Sommermeyer, Thomas Glaser, Reilinde Wittka, Jean-Marie-Viktor de Vry